Hrt Financial LP Cyma Bay Therapeutics, Inc. Transaction History

Hrt Financial LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$5.88 - $9.59 $1.83 Million - $2.99 Million	311,482 Added 419.82%	385,676 $3.36 Million
Q4 2022 Feb 10, 2023	BUY	$3.22 - $6.27 $238,904 - $465,196	74,194 New	74,194 $465,000
Q4 2021 Feb 14, 2022	SELL	$3.23 - $4.6 $167,485 - $238,523	-51,853 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.47 - $4.42 $179,929 - $229,190	51,853 New	51,853 $189,000
Q1 2021 May 17, 2021	SELL	$4.23 - $6.55 $441,582 - $683,774	-104,393 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$5.73 - $9.03 $598,171 - $942,668	104,393 New	104,393 $599,000
Q3 2020 Nov 13, 2020	SELL	$3.32 - $7.24 $46,028 - $100,375	-13,864 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $19,548 - $58,922	13,864 New	13,864 $48,000
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $30,101 - $134,213	-22,633 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$5.12 - $7.21 $115,880 - $163,183	22,633 New	22,633 $115,000
Q4 2018 Feb 15, 2019	SELL	$6.54 - $11.74 $161,596 - $290,083	-24,709 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$10.88 - $14.52 $268,833 - $358,774	24,709 New	24,709 $273,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.